Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 18/20 | 0.61 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.53 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2127682 | 1.00 | CHRM3 (0.61) | CHRM3CYP2B6KCNN4 | |
| SCHEMBL1682974 | 1.00 | CHRM3 (0.61) | CHRM3CYP2B6KCNN4 | |
| SCHEMBL2126929 | 1.00 | CHRM3 (0.61) | CHRM3CYP2B6KCNN4 | |
| SCHEMBL4736385 | 0.98 | CHRM3 (0.63) | CHRM3CYP2B6KCNN4 | |
| SCHEMBL3053742 | 0.93 | CHRM3 (0.58) | CHRM3CYP2B6KCNN4 | |
| SCHEMBL2128020 | 0.85 | SMN1; SMN2 (0.52) | CHRM3KCNN4 | |
| SCHEMBL2126812 | 0.85 | CHRM3 (0.62) | CHRM3KCNN4 | |
| SCHEMBL4738208 | 0.85 | CHRM3 (0.62) | CHRM3 | |
| SCHEMBL4736843 | 0.84 | CHRM3 (0.66) | CHRM3KCNN4 | |
| SCHEMBL3043721 | 0.83 | CYP2B6 (0.59) | CHRM3CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121137-B1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2012-04-25 | — | — | EP | disclosed |
| EP-2121137-B1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2012-04-25 | — | — | EP | disclosed |
| WO-2011073662-A1 | COMBINATION OF A BENZOXAZINONE AND A FURTHER AGENT FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | WO | disclosed |
| US-20100144606-A1 | COMBINATION 408 | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100113510-A1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113510-A1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | US | disclosed |
| WO-2009153536-A1 | 1-AZA-BICYCLO [2.2.2] OCTANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| WO-2008075006-A1 | PIPERLDINUM COMPOUNDS FOR TREATMENT OF OBSTRUCTIVE PULMONARY DISEASES ( COPD) | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075005-A1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144606-A1 | COMBINATION 408 | NR3C2, PTGER2, LTB4R2 | CHRM3 656/4885CYP2B6 2982/4885KCNN4 310/4885 |
| US-20100113510-A1 | QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885CYP2B6 401/4885KCNN4 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.